Abstract
Introduction: Cisplatin vinorelbine adjuvant chemotherapy significantly improves survival in resected NSCLC. We evaluated outcomes of patients receiving adjuvant chemotherapy in our institution between 2006 2011. Methods: Outcomes of stage IB IIIA NSCLC patients who received platinum vinorelbine following radical lung surgery were collected and analysed to assess overall survival (OS), progression-free survival (PFS), and treatment intensity. Results: 53 patients were identified (M:F, 23:30), mean age 62, and 35% were adenocarcinoma. Resected stages were IB-IIIA, with 33% staged IIIA. When tested, EGFR mutation prevalence was 33% (39% never smokers; 61% ever smokers). Median chemotherapy cycles given was 4 with no toxicity related deaths. There was no difference in PFS or OS in patients having carboplatin compared with cisplatin. Significantly improved OS in patients that received 3 cycles of chemotherapy was observed (HR = 0.25, 0.07 0.97, p = 0.04). Updated results will be presented at the Annual Meeting. Conclusion: Our small dataset indicates that four cycles of adjuvant platinum vinorelbine chemotherapy is deliverable in the real world setting, and that less than 3 chemotherapy cycles is associated with poorer outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
